The Partners Demonstration Project is a multi-national collaborative study to evaluate implementation of ART and PrEP for HIV-1 prevention in African heterosexual HIV-1 serodiscordant couples.
Phase III, multi-site, randomized, double-blind, placebo-controlled study of tenofovir and emtricitabine/tenofovir for pre-exposure prophylaxis (PrEP) to reduce HIV acquisition among HIV uninfected partners in HIV discordant couples.
This study proposes to develop a coordinated, multi-component HIV prevention package of evidence-based biomedical and behavioral interventions that will be individually-tailored and targeted to maximize coverage and impact on HIV incidence in an African population.
The goal of the study is to understand the specific characteristics of immune responses that protect the uninfected partner of HIV discordant couples and the SIV infection in rhesus macaques.
This study is to determine whether higher doses of acyclovir lead to greater reductions in HIV levels in plasma and genital tract than the doses used in the prior studies.
Phase III, multi-site, randomized, double-blind, placebo-controlled study to determine whether people infected with herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes, can reduce their risk of becoming infected with HIV by using acyclovir, an approved medicine that suppresses genital herpes.
Phase III, multi-site, randomized, double-blind, placebo-controlled study to determine whether the use of acyclovir by people who are infected with both HSV-2 and HIV can reduce the likelihood that they will transmit HIV to their HIV uninfected sexual partners.